Fig. 4: Expansion of CAR-T after injection, monitored by flow cytometry. | Bone Marrow Transplantation

Fig. 4: Expansion of CAR-T after injection, monitored by flow cytometry.

From: Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma

Fig. 4

Blue points: Control group; Red points: Early G-CSF group. a Relative AUC 0–28 calculated with R (https://www.R-project.org/) and for patients treated with Axi-cel or Tisa-cel and with at least 3 points of CAR-T expansion follow-up. b Absolute AUC 0–28 calculated with R and for patients treated with Axi-cel or Tisa-cel and with at least 3 points of CAR-T expansion follow-up. c Relative Cmax (maximum concentration detected in % CAR-T/CD3+ T cells) for patients treated with Axi-cel or Tisa-cel. d Absolute Cmax (maximum concentration detected in number of CAR-T cells/µL) for patients treated with Axi-cel or Tisa-cel.

Back to article page